# NAD injection: Parenteral and Subcutaneous NAD+ Research, Routes and Evidence > NAD injection covers the parenteral routes — IV, intramuscular, subcutaneous. Research digest of what the injectable NAD+ literature measured, where peer-reviewed pharmacokinetic data are thin. The injectable route family — intravenous, intramuscular, subcutaneous — and how little peer-reviewed pharmacokinetic data exist outside small NADH studies in Parkinson's research. ## The gist A NAD injection puts NAD+ (the cell's energy-handling helper molecule) into the body through a needle rather than the gut — into a vein, a muscle, or under the skin. The whole point is to bypass poor oral absorption. The catch: outside a handful of small NADH studies in Parkinson's disease, there is very little rigorous pharmacokinetic data on any injected NAD+ route, and these are compounded, unapproved preparations [5]. This page describes what the published parenteral studies measured and is explicit about how thin that evidence is. No product, no dose recommendation. ## The parenteral route family for NAD+ "NAD injection" is an umbrella over several parenteral routes, all sharing one logic: deliver NAD+ or NADH directly to the bloodstream or tissue, bypassing the gut where intact NAD+ is poorly absorbed [5]. The routes studied or marketed are intravenous infusion, intramuscular and subcutaneous injection, and — at the margins of evidence — sublingual, intranasal and transdermal patch delivery, the last of which has little controlled support [5]. The peer-reviewed pharmacokinetic record across these routes is sparse. The clearest human parenteral data come from a comparison of oral and parenteral NADH application in Parkinson's disease, where the orally applied form produced overall disability improvement comparable to the parenteral form in a large open-label series [9]. What is largely missing is rigorous head-to-head pharmacokinetics for injected NAD+ specifically — absorption, distribution and clearance by route — outside the IV clearance pilot summarized on the [NAD infusion research](/nad-infusion) page. ## What injectable NAD+ studies have and have not measured Searches for NAD+ injection benefits deserve a precise answer: the cited parenteral studies measured clinical-rating and pharmacokinetic endpoints in small populations, not a broad benefit. In a double-blind study, intravenous-then-intramuscular NADH (25 mg) in Parkinson's patients produced only a non-significant tendency to improve, indistinguishable from saline [7]. An open prospective study of intravenous NADH (10 mg over 30 minutes for 7 days) reported a significant UPDRS improvement and increased plasma levodopa availability [8], and a large open-label series reported about 80% of patients improving across oral and parenteral routes [9]. What these studies have not measured is just as important. There is no randomized, placebo-controlled trial demonstrating that injected NAD+ improves a hard clinical outcome; the strongest controlled signal (the NADH Parkinson's work) was null [7], and the favorable reports were open-label and uncontrolled [8][9]. Mechanistic preclinical data — intravenous NAD+ reducing rat myocardial infarct size by about 85% at 20 mg/kg [11] — show biological plausibility, not human benefit. The injectable evidence base supports curiosity, not claims. ## The status of injectable NAD+: compounded, unapproved, quality-variable Injectable NAD+ is not an FDA-approved medicine. It is compounded, and a compounded injectable NAD+ product was subject to an FDA Class I recall for elevated endotoxin [5] — the documented quality risk of the route. Reconstituted injectable NAD+ is also chemically delicate: NAD+ is hygroscopic and degrades with heat and moisture, so injectable solutions are kept cold and protected from light [5]. Weighed honestly, the injectable route trades a real pharmacological advantage (bypassing poor oral uptake) for a real evidence and quality gap (no controlled efficacy, documented contamination risk). This digest reports both sides and recommends neither use nor avoidance — those are clinical judgments, not editorial ones. ## What is an NAD injection? An NAD injection delivers NAD+ (or NADH) parenterally — intravenously, intramuscularly or subcutaneously — bypassing the gut. These are compounded, unapproved wellness preparations, and peer-reviewed pharmacokinetic data are limited to small studies, mostly NADH in Parkinson's research [7][8][9]. It is a delivery route, not an approved treatment. ## Is NAD+ shot worth it? The controlled evidence for injectable NAD+ is thin. Small open-label NADH studies in Parkinson's reported improvement [8][9], but placebo-controlled work showed no significant difference from saline [7], so the research base does not support strong efficacy claims. "Worth it" is a clinical and personal judgment this digest cannot make for you. ## When should you inject NAD+? No validated timing protocol exists in the peer-reviewed literature. Published parenteral studies used fixed research schedules — for example 10 mg NADH over 30 minutes for 7 days [8] — which are study designs, not dosing instructions. This site reports protocols as study parameters, never as guidance for an individual. --- A terrazzo-bright reading of the NAD+ literature — the coenzyme scattered apart from the NMN and NR precursors that rebuild it, the oral trials that moved blood NAD+ set in their own panels from the rapidly-cleared IV drip and the recalled compounded injectable, each claim stamped to its study and each gap left in plain view; no clinic behind the confetti and nothing here infused, injected, dosed, or sold.